How ADCs Are Transforming HER2+ Metastatic Breast Cancer: Discover the Latest Clinical Trend - a podcast by ReachMD

CME credits: 0.25

Valid until: 07-07-2022

Claim your CME credit at https://reachmd.com/programs/cme/how-adcs-are-transforming-her2-metastatic-breast-cancer-discover-the-latest-clinical-trend/12690/

While HER2+ breast cancers are traditionally associated with a poor prognosis, the development of HER2-directed treatment strategies has led to substantial and durable survival improvements, even in patients with metastatic disease. Nonetheless, a percentage of these patients will not respond to certain therapies, and many may become resistant within a year of treatment.

In this chapterized activity, Dr. Javier Cortes and Dr. Sara Hurvitz discuss optimal therapy selection based on individual patient characteristics as well as strategies to manage potential adverse events associated with current treatment options for HER2+ metastatic breast cancer.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD